Eli Lilly CDR (CAD Hedged)
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 43K
- Market Cap
- $859.4B
- Introduction
Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.
A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis
- Conditions
- Ulcerative ColitisUlcerative Colitis Chronic
- Interventions
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2025-04-18
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 140
- Registration Number
- NCT06598943
- Locations
- 🇺🇸
Southern California GI and Liver Centers (SCLC), Coronado, California, United States
🇺🇸Om Research, LLC, Lancaster, California, United States
🇺🇸United Medical Doctors, Los Alamitos, California, United States
A Study of LY4065967 in Healthy Japanese Participants
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2025-04-03
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 59
- Registration Number
- NCT06594159
- Locations
- 🇯🇵
Souseikai Fukuoka Mirai Hospital, Fukuoka, Japan
MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors
- Conditions
- Pancreatic Ductal AdenocarcinomaNon-small Cell Lung CancerColorectal Cancer
- Interventions
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2025-04-22
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 540
- Registration Number
- NCT06586515
- Locations
- 🇺🇸
City of Hope, Duarte, California, United States
🇺🇸University of California, Los Angeles (UCLA), Los Angeles, California, United States
🇺🇸Sarah Cannon Research Institute at HealthOne, Denver, Colorado, United States
A Study of Orforglipron for the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities (ATTAIN-MAINTAIN)
- Conditions
- ObesityOverweight
- Interventions
- Drug: Placebo
- First Posted Date
- 2024-09-05
- Last Posted Date
- 2025-04-20
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 300
- Registration Number
- NCT06584916
- Locations
- 🇺🇸
Cahaba Research, Birmingham, Alabama, United States
🇺🇸Cahaba Research - Pelham, Pelham, Alabama, United States
🇺🇸Southern California Dermatology, Inc., Santa Ana, California, United States
Effects of LY3848575 Versus Placebo in Participants With Painful Distal Sensory Polyneuropathy
- Conditions
- Neuropathic PainDistal Sensory Polyneuropathy
- Interventions
- Drug: Placebo
- First Posted Date
- 2024-08-23
- Last Posted Date
- 2025-04-18
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 450
- Registration Number
- NCT06568042
- Locations
- 🇺🇸
Alpine Clinical Research Center, Boulder, Colorado, United States
🇩🇪emovis GmbH, Berlin, Germany
🇺🇸MD First Research - Chandler, Chandler, Arizona, United States
A Real-World Comparative Study of Donanemab (LY3002813) Plus Usual Care Versus Usual Care Alone in US Participants With Early Symptomatic Alzheimer's Disease
- First Posted Date
- 2024-08-22
- Last Posted Date
- 2025-02-12
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 3060
- Registration Number
- NCT06566170
- Locations
- 🇺🇸
Rehabilitation & Neurological Services, Huntsville, Alabama, United States
A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors
- Conditions
- Metastatic Solid TumorSMARCA4-Deficient TumorAdvanced Solid TumorNon-small Cell Lung Cancer
- Interventions
- First Posted Date
- 2024-08-20
- Last Posted Date
- 2025-01-28
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 160
- Registration Number
- NCT06561685
- Locations
- 🇯🇵
National Cancer Center Hospital East, Kashiwa, Chiba, Japan
🇯🇵Shizuoka Cancer Center, Nagaizumi-cho,Sunto-gun, Shizuoka, Japan
🇺🇸Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States
A Study of LY3532226 in Participants With Obesity
- First Posted Date
- 2024-08-16
- Last Posted Date
- 2025-04-20
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 105
- Registration Number
- NCT06557356
- Locations
- 🇺🇸
Fortrea Clinical Research Unit, Madison, Wisconsin, United States
🇸🇬Lilly Centre for Clinical Pharmacology, Singapore, Singapore
A Study of Mevidalen (LY3154207) in Participants With Alzheimer's Disease
- First Posted Date
- 2024-08-05
- Last Posted Date
- 2025-04-18
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 300
- Registration Number
- NCT06538116
- Locations
- 🇺🇸
Banner Alzheimer's Institute, Phoenix, Arizona, United States
🇺🇸Baptist Health Center for Clinical Research, Little Rock, Arkansas, United States
🇺🇸Profound Research, LLC, Carlsbad, California, United States
A Study of Subcutaneous Injection in Healthy Participants
- Conditions
- Healthy
- Interventions
- Device: Syringe Pump
- First Posted Date
- 2024-07-24
- Last Posted Date
- 2024-07-24
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 32
- Registration Number
- NCT06516913
- Locations
- 🇺🇸
Fortrea CRU, Inc., Dallas, Texas, United States